Use of AI in Genetic Diagnosis: Identifying Rare Diseases

By HEOR Staff Writer

May 17, 2024

Introduction

Every year, numerous children are born with severe genetic disorders, with a considerable number remaining undiagnosed due to the complexity of identifying causative genetic variants. The emergence of artificial intelligence (AI) in genetic diagnosis offers a promising avenue for addressing these challenges, pushing the boundaries of precision medicine.

Understanding the Diagnostic Challenge

Genetic disorders, often resulting from single-gene mutations, present a significant diagnostic challenge. Despite modern bioinformatics tools, the process of pinpointing the exact variant responsible for a disease remains a complex task, demanding both time and extensive knowledge. Despite the advent of sophisticated bioinformatics tools, the diagnostic rate for genetic disorders hovers between 30 and 40%.  This complexity underscores the need for more efficient diagnostic methodologies.

Figure 1. Schematic Diagram Illustrating the Reanalysis Process

The Power of AI in Genetic Analysis

AI systems, such as AI-MARRVEL (AIM), have been developed to enhance the diagnostic process for Mendelian disorders. These systems leverage patient clinical features and sequencing profiles, offering a sophisticated approach to variant prioritisation. AIM, in particular, is trained on a more than 3.5 million variant data points and curated by certified experts, embodying a significant leap forward in genetic diagnostics.

Navigating the Limitations of Current Tools

While AI systems like AIM mark a significant advancement, they are not without limitations. The inability to analyse certain types of genetic variations and a focus on coding variants restrict their scope. However, these challenges present opportunities for further innovation and integration of more comprehensive analytical tools.

The Future of Genetic Diagnosis

AI in genetic diagnosis is not just a theoretical concept but a practical tool with a web interface for real-world application. It has the potential to truly enhance the periodic reanalysis of undiagnosed cases, making it a feasible and cost-effective option for many. As AI continues to evolve, its integration into clinical practice promises to enhance patient outcomes and set a new norm in genetic medicine.

Reference url

Recent Posts

NICE Endorses Obecabtagene Autoleucel Therapy for Adult Relapsed B-Cell Leukaemia

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-developed chimeric antigen receptor (CAR) T-cell trea...
Accelerating Access to Latin America Innovative Therapies Through Collaboration and Innovation
Accelerating Access to Latin America Innovative Therapies In this update we outline a strategic vision for transforming Latin America's healthcare systems through innovation, collaboration, and equitable access, with a stron...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before Phase 3

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must occur earlier in drug development—ideally before Ph...